Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $11000.0.

  • BioXcel Therapeutics' Other Operating Expenses fell 9905.98% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $963000.0, marking a year-over-year decrease of 5246.79%. This contributed to the annual value of $2.1 million for FY2024, which is 7007.94% up from last year.
  • BioXcel Therapeutics' Other Operating Expenses amounted to $11000.0 in Q3 2025, which was down 9905.98% from $107000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Other Operating Expenses high stood at $1.2 million for Q3 2024, and its period low was $9000.0 during Q4 2022.
  • Over the past 4 years, BioXcel Therapeutics' median Other Operating Expenses value was $62000.0 (recorded in 2024), while the average stood at $273538.5.
  • As far as peak fluctuations go, BioXcel Therapeutics' Other Operating Expenses skyrocketed by 783333.33% in 2023, and later plummeted by 9905.98% in 2025.
  • BioXcel Therapeutics' Other Operating Expenses (Quarter) stood at $9000.0 in 2022, then skyrocketed by 7833.33% to $714000.0 in 2023, then grew by 16.39% to $831000.0 in 2024, then tumbled by 98.68% to $11000.0 in 2025.
  • Its Other Operating Expenses stands at $11000.0 for Q3 2025, versus $107000.0 for Q2 2025 and $14000.0 for Q1 2025.